One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.

Like any relationship, a patient-doctor one has rules about how to engage and communicate. They’re typically in writing, bearing the patient’s signature of agreement. I’ve seen the rules posted on ...

May is Lupus Awareness Month, and the Lupus Foundation of America is calling on supporters to join efforts to bring attention to lupus, an autoimmune disease whose symptoms are not always readily ...

The U.S. Food and Drug Administration (FDA) has granted fast track status to ADI-001, Adicet Bio’s CAR T-cell therapy for systemic lupus erythematosus (SLE) that’s resistant to available treatments, ...

As we flip the page to a new year, the pull of hustle culture on social media hasn’t seemed to change. Messages urge us to do more, achieve more, and push harder. But for those of us living with lupus ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to experimental cell therapy SC291 as a potential treatment for hard-to-manage systemic lupus erythematosus (SLE). Fast ...

Treatment with dapirolizumab pegol is better than a placebo at controlling disease activity in people with systemic lupus erythematosus (SLE), according to new results from a Phase 3 clinical trial.

There are six white seashells covered in sand that have been washed ashore by Lake Pontchartrain onto Lincoln Beach in New Orleans. It took me nearly half an hour to reach the spot where they lay.

In the past three decades of dealing with unpredictable health issues, a pain point has reared its head over and over again for me. After countless conversations with other chronic illness warriors, I ...

When the protein TLR7, or toll-like receptor 7 — which normally triggers an immune response against viruses and bacteria — instead builds up in immune cells, the immune system may turn against its own ...

The Lupus Foundation of America (LFA) will use a three-year federal grant — worth up to $500,000 per year — to continue efforts to increase the number of Black lupus patients in the U.S. who ...

Brepocitinib, an investigational oral therapy, failed to show any benefits beyond a placebo in a Phase 2 clinical trial that tested it in adults with moderate to severely active systemic lupus ...